We are proud to announce that we have secured a $1.8 million grant from the National Institutes of Health (NIH) to accelerate our development of a potential cure for diabetes. This is a major milestone in the fight against one of the world’s most widespread chronic diseases.
A Major Step Toward a Functional Cure
With this new funding, we are poised to move our stem cell-based therapy for diabetes to the next stage of testing. Our revolutionary approach uses humaninduced pluripotent stem cells (iPSCs) to create insulin-producing cells known as Islet-Like Clusters (ILCs), that can be transplanted into the body to restore insulin production and regulate blood glucose levels.
“This grant brings real hope for anyone suffering from diabetes,” said Anthony Kolton, CEO of RMS. “We’re one step closer to a functional cure, which would be life-changing for anyone affected by the disease.”
Addressing the Limitations of Current Treatments
Currently, the only way to replace insulin-producing cells is through organ donation, which requires recipients to take lifelong immunosuppressive drugs, often accompanied by serious risks and side effects. We aim to eliminate that barrier by developing ILCs that are:
- Created in unlimited supply
- Safe for implantation
- Resistant to immune system rejection
The NIH grant will enable RMS to complete its proof-of-concept research, including a critical “humanized” mouse model study, building on the success of previous labbased experiments.
A Call to Visionary Investors
RMS is actively inviting investors and strategic partners to join its mission to transform diabetes treatment. According to Mr. Kolton, “It’s a great opportunity to get behind a worthwhile cause and see a potential return on investment.”
In addition to its scientific progress, RMS has already attracted the interest of major pharmaceutical companies and expects a strategic acquisition within the next two years.
For Wisconsin-based investors, the opportunity is even more attractive: the state is offering a 25% tax credit on eligible investments in RMS.
Learn More or Get Involved
Interested investors can contact Tom Joyce at tjoyce@regenmedsolutions.com or contact us for more information.